Clin Exp Emerg Med.  2024 Mar;11(1):94-99. 10.15441/ceem.23.051.

Tranexamic acid for angiotensin-converting enzyme inhibitor–induced angioedema

• Pathak GN
• Truong TM
• Chakraborty A
• Rao B
• Monteleone C

• KMID: 2555267
• DOI: http://doi.org/10.15441/ceem.23.051

Abstract

Approximately 0.7% of patients taking angiotensin-converting enzyme inhibitors (ACEIs) develop ACEI-induced angioedema (ACEI-IA). With no approved treatments for ACEI-IA, the risk of complications is concerning. Tranexamic acid (TXA) has the potential to prevent intubations and resolve ACEI-IA by inhibiting the downstream production of bradykinin. In this review, we aim to evaluate the safety and efficacy of TXA use in ACEI-IA. We queried the PubMed database for studies involving TXA for ACEI-IA from January 2003 to January 2023. Seven studies met the study inclusion criteria. Our results demonstrate that TXA may improve angioedema symptoms and prevent intubation. In addition, its availability, low cost, and safety profile support its use for improving the symptoms and complications of ACEI-IA in an emergency setting.

Keyword

Angiotensin-converting enzyme inhibitor–induced angioedema; Bradykinin-mediated angioedema; Tranexamic acid; Angiotensin-converting enzyme inhibitors; Drug-induced angioedema